MarketBeat's Top 5 Rated Small-Cap Stocks [Yahoo! Finance]
Trevi Therapeutics, Inc. (TRVI)
Company Research
Source: Yahoo! Finance
MarketBeat's top-rated small-cap names highlight where analyst conviction is strongest, spanning profitable healthcare plays, rate-sensitive financials, and high-growth biotech innovators. While volatility remains elevated, strong analyst sentiment and improving fundamentals suggest select small-cap opportunities could outperform as easing financial conditions carry into 2026. Interested in Trevi Therapeutics, Inc.? Here are five stocks we like better. As the market pushes toward year-end highs and the holiday season is in full force, optimism and speculation have returned. Major indices continue to hover near record levels, volatility remains contained, and investors are increasingly positioning for a more accommodative monetary backdrop in 2026. With interest rates moving lower and the Federal Reserve officially ending its quantitative tightening program on Dec. 1, market conditions are beginning to resemble the early stages of a renewed easing cycle. That shift has reignited
Show less
Read more
Impact Snapshot
Event Time:
TRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVI alerts
High impacting Trevi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRVI
News
- Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)PR Newswire
- Is Trevi Therapeutics (TRVI) Building a Multi-Indication Moat With Its Nalbuphine ER Cough Strategy? [Yahoo! Finance]Yahoo! Finance
- Trevi Therapeutics (TRVI) Valuation Check After FDA End Of Phase 2 Update And Renewed Analyst Optimism [Yahoo! Finance]Yahoo! Finance
- Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.MarketBeat
- Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $19.00 price target on the stock.MarketBeat
TRVI
Earnings
- 11/13/25 - Beat
TRVI
Sec Filings
- 2/5/26 - Form SCHEDULE
- 1/30/26 - Form SCHEDULE
- 1/12/26 - Form 4
- TRVI's page on the SEC website